SANTA BARBARA, Calif.--(BUSINESS WIRE)--Oct. 10, 2005--Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical development company specializing in PhotoPoint(R) photodynamic therapy (PDT), today confirmed that patient enrollment is underway in its Phase III clinical trial of PHOTREX(TM) (SnET2) for wet age-related macular degeneration (AMD). This multi-center, placebo controlled study is a confirmatory trial designed to fulfill the requirements for additional clinical data as outlined in an "approvable" letter received from the FDA following its review of the company's NDA submission.